Skip to main content Accessibility help
×
Home
  • Print publication year: 2015
  • Online publication date: July 2015

Chapter 20 - Psychopharmacology and motherhood

from Section 4 - Child, parent, and family interventions
Abel, K. M. (2013). Fetal antipsychotic exposure in a changing landscape: seeing the future. British Journal of Psychiatry, 202, 321–3.
Adams, J., Lui, C.-W., Sibbritt, D., et al. (2009). Women’s use of complementary and alternative medicine during pregnancy: a critical review of the literature. Birth, 36, 237–45.
Bellantuono, C., Tofani, S., Di Sciascio, G., et al. (2013). Benzodiazepine exposure in pregnancy and risk of major malformations: a critical overview. General Hospital Psychiatry, 35, 38.
Black, R. A., and Hill, D. A. (2003). Over-the-counter medications in pregnancy. American Family Physician, 67, 2517.
Bodén, R., Lundgren, M., Brandt, L., et al. (2012). Antipsychotics during pregnancy: relation to fetal and maternal metabolic effects. Archives of General Psychiatry, 69, 715–21.
Buchanan, T. A., and Xiang, A. H. (2005). Gestational diabetes mellitus. Journal of Clinical Investigation, 115, 485–91.
Budzynska, K., Gardner, Z. E., Dugoua, J. J., et al. (2012). Systematic review of breastfeeding and herbs. Breastfeeding Medicine, 7, 489503.
Byatt, N., Deligiannidis, K. M., and Freeman, M. P. (2013). Antidepressant use in pregnancy: a critical review focused on risks and controversies. Acta Psychiatrica Scandinavica, 127, 94114.
Clark, C. T., Klein, A. M., Perel, J. M., et al. (2013). Lamotrigine dosing for pregnant patients with bipolar disorder. American Journal of Psychiatry, 170, 1240–7.
Clifton, V. L. (2010). Review: sex and the human placenta: mediating differential strategies of fetal growth and survival. Placenta, 31 (Suppl), S33-9.
Cohen, A., McCubbin, D. M., Collin, J., et al. (2001). Medications as social phenomena. Health, 5, 441–69.
Davanzo, R., Copertino, M., De Cunto, A., et al. (2011). Antidepressant drugs and breastfeeding: a review of the literature. Breastfeeding Medicine, 6, 8998.
Dayan, J., Graignic-Philippe, R., Seligmann, C., et al. (2011). Use of antipsychotics and breastfeeding. Current Women’s Health Reviews, 7, 3745.
Einarson, A., and Boskovic, R. (2009). Use and safety of antipsychotic drugs during pregnancy. Journal of Psychiatric Practice, 15, 183–92.
Engeland, A., Bjørge, T., Daltveit, A. K., et al. (2012). Effects of preconceptional paternal drug exposure on birth outcomes: cohort study of 340 000 pregnancies using Norwegian population-based databases. British Journal of Clinical Pharmacology, 75, 1134–41.
Facchinetti, F., Pedrielli, G., Benoni, G., et al. (2012). Herbal supplements in pregnancy: unexpected results from a multicentre study. Human Reproduction, 27, 3161–7.
Fortinguerra, F., Clavenna, A., and Bonati, M. (2009). Psychotropic drug use during breastfeeding: a review of the evidence. Pediatrics, 124, e547–56.
Fasouliotis, S. J., and Schenker, J. G. (2000). Maternal–fetal conflict. European Journal of Obstetrics & Gynecology and Reproductive Biology, 89, 101–7.
Galbally, M., Snellen, M., Walker, S., et al. (2010). Management of antipsychotic and mood stabilizer medication in pregnancy; recommendations for antenatal care. Australian & New Zealand Journal of Psychiatry, 44, 99108.
Gentile, S. (2008). Infant safety with antipsychotic therapy in breast feeding: a systematic review. Journal of Clinical Psychiatry, 69, 666–73.
Gentile, S. (2010). Antipsychotic therapy during early and late pregnancy: a systematic review. Schizophrenia Bulletin, 36, 518–44.
Graves, J. A. (2010). Review: sex chromosome evolution and the expression of sex-specific genes in the placenta. Placenta, 31 (Suppl), S27–32.
Gurung, R. A. R. (2013). A multicultural approach to health psychology. American Journal of Lifestyle Medicine, 7, 412.
Higginbottom, G. M. A., Safipour, J., Mumtaz, Z., et al. (2013). “I have to do what I believe”: Sudanese women’s beliefs and resistance to hegemonic practices at home and during experiences of maternity care in Canada. BMC Pregnancy and Childbirth, 13(51).
Howard, L. M., Goss, C., Leese, M., et al. (2004). The psychosocial outcome of pregnancy in women with psychotic disorders. Schizophrenia Research, 71, 4960.
Isoherranen, N., and Thummel, K. E. (2013). Drug metabolism and transport during pregnancy: how does drug disposition change during pregnancy and what are the mechanisms that cause such changes? Drug Metabolism and Disposition, 41, 256–62.
Jensen, T. B., Gerds, T. A., Grøn, R., et al. (2013). Risk factors for venous thromboembolism during pregnancy. Pharmacoepidemiology and Drug Safety, 22, 1283–91.
La Torre, D., and Falorni, A. (2007). Pharmacological causes of hyperprolactinemia. Therapeutic Clinical Risk Management, 3, 929–51.
Le Houezec, J., and Aubin, H. J. (2013). Pharmacotherapies and harm-reduction options for the treatment of tobacco dependence. Expert Opinion on Pharmacotherapy, 14, 1959–67.
Lin, H. C., Chen, I. J., Chen, Y. H., et al. (2010). Maternal schizophrenia and pregnancy outcome: does the use of antipsychotics make a difference? Schizophrenia Research, 116, 5560.
Louik, C., Gardiner, P., Kelley, K., et al. (2010). Use of herbal treatments in pregnancy. American Journal of Obstetrics and Gynecology, 202, 439 e1–10.
Malek, A., and Mattison, D. R. (2010). Drug development for use during pregnancy: impact of the placenta. Expert Review of Obstetrics and Gynecology, 5, 437–54.
McKean, M. (2013). Psychiatric care during pregnancy and postpartum. II. Management of anxiety, psychosis, and lactation. Psychopharm Review, 48, 2531.
McNeil, T. F., Kaij, L., and Maimquist-Larsson, A. (1984). Women with nonorganic psychosis: pregnancy’s effect on mental health during pregnancy. Acta Psychiatrica Scandinavica, 70, 140–8.
Morrow, J., Russell, A., Guthrie, E., et al. (2006). Malformation risks of antiepileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register. Journal of Neurology, Neurosurgery and Psychiatry, 77, 193–8.
Murphy, E., and McMahon, F. J. (2013). Pharmacogenetics of antidepressants, mood stabilizers, and antipsychotics in diverse human populations. Discovery Medicine, 16, 113–22.
Oesterheld, J. R., Cozza, K., and Sandson, N. B. (2008). Oral contraceptives. Psychosomatics, 49, 168–75.
Peters, S., Lind, J. L., Humphrey, J. R., et al. (2013). Safe lists for medications in pregnancy: inadequate evidence base and inconsistent guidance from Web-based information, 2011. Pharmacoepidemiology and Drug Safety, 22, 324–8.
Sachs, H. C., and Committee on Drugs (2013). The transfer of drugs and therapeutics into human breast milk: an update on selected topics. Pediatrics, 132, e797e809.
Sadowski, A., Todorow, M., Brojeni, P. Y., et al. (2013). Pregnancy outcomes following maternal exposure to second-generation antipsychotics given with other psychotropic drugs: a cohort study. BMJ Open, 3, e003062.
Seeman, M. V. (2012). Antipsychotic-induced somnolence in mothers with schizophrenia. Psychiatric Quarterly, 83, 83–9.
Seeman, M. V., and Ross, R. (2011). Prescribing contraceptives for women with schizophrenia. Journal of Psychiatric Practice, 17, 258–69.
Seeman, M. V., and Seeman, N. (2012). The meaning of antipsychotic medication to patients with schizophrenia. Journal of Psychiatric Practice, 18, 338–48.
US Food and Drug Administration (2011). Washington, DC (www.fda.gov/Drugs/DrugSafety/ucm243903.htm#list).
van der Geest, S., Whyte, S. R., and Hardon, A. (1996). Anthropology of pharmaceuticals: a biographical approach. Annual Review of Anthropology, 25, 153–78.
Vemuri, M., and Williams, K. (2011). Treating bipolar disorder during pregnancy: optimal outcomes require careful preconception planning, medication risk/benefit analysis. Current Psychiatry, 10, 5866.
Werler, M. M., Mitchell, A. A., Hernandez-Diaz, S., et al. (2005). Use of over-the-counter medications during pregnancy. American Journal of Obstetrics and Gynecology, 193, 771–7.
Wichman, C. L. (2009). Atypical antipsychotic use in pregnancy: a retrospective review. Archives of Women’s Mental Health, 12, 53–7.
Wilkie, M. J. V., Smith, G., Day, R. K., et al. (2009). Polymorphisms in the SLC6A4 and HTR2A genes influence treatment outcome following antidepressant therapy. Pharmacogenomics Journal, 9, 6170.
Yonkers, K. A., Vigod, S., and Ross, L. E. (2011). Diagnosis, pathophysiology, and management of mood disorders in pregnant and postpartum women. Obstetrics and Gynecology, 117, 961–77.
Yonkers, K. A., Wisner, K. L., Stowe, Z., et al. (2004). Management of bipolar disorder during pregnancy and the postpartum period. American Journal of Psychiatry, 161, 608–20.